Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02880943
Other study ID # EIFFEL
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received August 18, 2016
Last updated November 7, 2016
Start date October 2016
Est. completion date February 2021

Study information

Verified date November 2016
Source Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santéFrance: Ethics Committee
Study type Interventional

Clinical Trial Summary

This is a prospective, multicentre, open-label, phase I/II study to evaluate the maximum tolerated dose (MTD), and the most successful dose (MSD) of XOFIGO®, in renal cancer patients with metastases to bone, without (Group A) or with (Group B) visceral metastases.


Description:

This is a prospective, multicentre, open-label, phase I/II study to evaluate the maximum tolerated dose (MTD), and the most successful dose (MSD) of XOFIGO®, in renal cancer patients with metastases to bone, without (Group A) or with (Group B) visceral metastases.

Dose-finding will be performed according to the Continual Reassessment Method (CRM) using either toxicity (escalation cohort) or joined toxicity-efficacy (expansion cohort) endpoints.

Two groups of patients will be evaluated:

- Group A: patients with bone disease mainly will be treated with XOFIGO® alone. (node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A).

- Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.

XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient. Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.

Starting dose for phase I will be 55 kBq/kg.

Visit schedule:

Selection Patients will come to the hospital at baseline, and screening assessments must be performed within 28 days prior to first XOFIGO® administration.

XOFIGO® period Patients will receive an injection of XOFIGO® on Day 1 of each 4 weeks-cycle for a maximum of 6 cycles. Patients will be subject to physical examination, blood sampling and pain evaluation prior to each injection. Scintigraphy of biodistribution of radium-223 dichloride will be realised on C1D1 after the 1st injection of XOFIGO® On C1D15, patients will also come for physical examination and blood sampling. On C2D15 (end of DLT period for phase I), patients will also come for end of DLT period evaluation and will be subject to physical examination and blood sampling.

Prior to C3D1 and C5D1, patients will undergo WB-IRM and FNa-PET. End of treatment visit (EOT) will take place 4 weeks after the last administration of XOFIGO®.

In the absence of confirmed bone progression at XOFIGO® discontinuation time, patients will continue to undergo WB-IRM and FNa-PET every 2 months until confirmed bone progression or end of follow-up.

Confirmation of bone progression upon WB-IRM will be performed 4 weeks after the initial progression is observed.

Follow-up Patients will be followed-up for a maximum of 12 months from the 1st administration of XOFIGO®.

Number of subjects:

Maximum number of patients to be enrolled in the escalation cohort is 21. Maximum number of patients to be enrolled in the expansion cohort is 21. Group A: 2-4 patients; Group B: 38-40 patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 42
Est. completion date February 2021
Est. primary completion date October 2020
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically confirmed metastatic renal cell carcinoma with a clear cell component.

2. Bone metastases upon bone scan with no CT and MRI performed any time within period of 4 weeks prior to study entry, with at least one evaluable unidimensional bone lesion (i.e., =1 malignant tumour mass that can be accurately measured in at least 1 dimension = 10 mm on T1-weighted Magnetic Resonance Imaging [MRI]).

Group A: bone metastases (lymph nodes and/or adrenal metastases, and/or = 5 lung metastases of less than 1 cm each, are allowed).

Group B: bone metastases AND visceral metastases upon MRI (according to revised RECIST 1.1 criteria).

3. Patient in a) first (naïve), or b) second or third line setting receiving or about to receive an approved Tyrosine Kinase Inhibitor (patients on mTOR inhibitors are not eligible).

4. Male or female, age =18 years at ICF signature time.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

6. Good or Intermediate prognostic group according to the International Metastatic Database Consortium (IMDC).

7. At least 4 weeks from the end of a previous systemic treatment, if any, with resolution of all treatment-related toxicity according to NCI CTCAE Version 4.03 grade = 1 except for alopecia.

8. Palliative local treatment allowed if performed = 2 weeks prior to study entry for radiotherapy, cementoplasty or minor surgery; = 4 weeks prior to study entry for major surgery.

9. Adequate organ function defined by the following criteria:

- Absolute Neutrophils count (ANC) =1 500 cells/mm3

- Platelets =100 000 cells/mm3

- Haemoglobin = 9.0 g/dL

- AST and ALT = 2.5 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT =5.0 x ULN

- Total bilirubin = 1.5 x ULN

- Estimated glomerular filtration rate upon MDRD = 50 mL/min

- Urinary protein < 2+ by urine dipstick. If dipstick is = 2+ then a 24-hour urine collection can be done and the patient may enter only if urinary protein is < 2 g per 24 hours

- Corrected calcium = 2.8 mmol/L.

10. Women of childbearing potential must have a negative serum pregnancy test within 7days prior to treatment initiation.

11. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrolment.

12. Willingness, for men and women,to use effective contraception during study treatment and for 6 months after last dose of study drug.

13. Willingness to comply with protocol requirements.

Exclusion Criteria:

Poor prognostic group according to the IMDC. 2. Prior radiotherapy to = 40% of bone marrow, whole pelvic irradiation and/or prior isotope therapy whatever the isotope (any a- or ß-emitters).

3. Active secondary cancer including prior malignancy from which the subject has been disease-free for = 3 years (however, adequately treated superficial basal cell skin or cervical carcinoma in situ before 4 weeks prior to entry are eligible to the study).

4. Known brain or leptomeningeal involvement. 5. Any other concurrent serious illness or medical conditions including:

- Crohn?s disease or ulcerative colitis

- Bone marrow dysplasia

- Known presence of osteonecrosis of the jaw 6. Uncontrolled hypertension. 7. Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure, or myocardial infarction within the last 6 months.

8. QTc interval (QTc) assessed by local device > 500ms in the 7 days prior to inclusion.

9. Ongoing biphosphonates, denosumab and/or vitamin D supplementation. 10. Active infection requiring systemic antibiotic or anti-fungal medication. 11. Any contra-indication to MRI, including:

- Carrying a metallic medical device (e.g. pacemaker) or foreign body prohibiting use of MRI

- Known allergy to gadolinium or iodine

- Dysthyroidism precluding usage of iodine contrast agent 12. Pregnant or breast feeding. 13. Participation in another clinical trial with any investigational drug within 30 days prior to study enrolment.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
XOFIGO
XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient. Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg. Starting dose for phase I will be 55 kBq/kg.

Locations

Country Name City State
France CHU Bordeaux (St. André) Bordeaux
France Centre François Baclesse Caen
France Hôpital Cochin Paris
France Hopital Europeen Georges Pompidou Paris
France Institut Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicities (DLT) Dose-limiting toxicities (DLT) within the first 6 weeks to determine the MTD.
DLT is defined as any XOFIGO related adverse event occurring between C1D1 and C2D15.
within 6 weeks after the first injection of XOFIGO Yes
Secondary Distribution of radium-223 dichloride into the bone assessed with scintigraphy of biodistribution of radium-223 dichloride Distribution of radium-223 dichloride into the bone assessed with scintigraphy of biodistribution of radium-223 dichloride Assessed at day 1 after the first Xofigo injection No
Secondary Bone response concordance between FNa-PET scan and whole-body MRI up to 12 months No
Secondary Bone clinical benefit rate (bone objective response or stable disease, BCB) up to 12 months No
Secondary Overall clinical benefit rate (bone and visceral objective response or stable disease, OCB) up to 12 months No
Secondary Changes in bone markers Changes in bone markers: bone formation: bone alkaline phosphatase [bALP], N-terminal type I collagen [PINP]; bone resorption: C-terminal telopeptide cross-linking of type I collagen [S-CTX-I], cross-linked C-terminal telopeptide of type I collagen [ICTP]), TRACP 5b, sRANKL, osteoprotegerin (OPG) up to 12 months No
Secondary Time to occurrence of the first Skeletal-Related Events (SRE) SRE including pathological fracture, requirement to initiate radiotherapy, spinal cord compression or requirement for bone surgery up to 12 months Yes
Secondary Time to bone progression (TTBP) defined as the time from the first administration of XOFIGO® to the bone tumour progression (revised RECIST 1.1 taking into account bone lesions) up to 12 months No
Secondary 1-year overall survival rate (1y-OS) defined as the percentage of patients alive 1 year after 1st administration of XOFIGO® 1 year No
Secondary Pain assessment upon Brief Pain Inventory (BPI) and analgesic consumption questionnaire BPI questionnaire will be completed 7 days before the first administration of XOFIGO® and before each visit. No
Secondary Change From Baseline in the FACT-Kidney Symptom Index-15 (FKSI-15) Scale FKSI-15 questionnaire will be performed only for patients included in the phase II part of the study. 7 months (Baseline and at 7 months) No
Secondary Changes in MRI New MRI criteria as prediction markers for progression and for disease specific and overall survival:
Diffusion weighted imaging (DWI): Apparent diffusion coefficient (ADC) values in the five target bone lesions
Ultra-short echo time (UTE) sequence: T2 measurements in the five target bone lesions
Perfusion weighted imaging (PWI): assessments of the area under the curve at 1min30, and of the focal lesion (FLE max) enhancement.
up to 12 months No
Secondary Change From Baseline in EQ-5D Scale EQ-5D questionnaire will be performed only for patients included in the phase II part of the study. 7 months (Baseline and at 7 months) No
See also
  Status Clinical Trial Phase
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Active, not recruiting NCT01996046 - FDG PET/CT in Breast Cancer Bone Mets
Completed NCT01358539 - Palliation: the Effect of Education on Pain Phase 3
Terminated NCT00981578 - ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain N/A
Completed NCT00762346 - Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Phase 4
Terminated NCT00757757 - A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases Phase 1/Phase 2
Completed NCT00420433 - Bone Response in Metastatic Breast Cancer Involving Bones N/A
Completed NCT02826382 - Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Early Phase 1
Terminated NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting NCT06367491 - National Database of Bone Metastases
Completed NCT03223727 - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
Completed NCT00830180 - Open Label Extension In Cancer Patients Phase 2
Active, not recruiting NCT03305224 - The Combination Therapy With Ra-223 and Enzalutamide Phase 2
Withdrawn NCT04109937 - External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial N/A
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00958477 - A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer Phase 1
Completed NCT03979118 - Exercise Prescription in Patients With Bone Metastases
Completed NCT03353090 - Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients N/A
Recruiting NCT05167669 - Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU Early Phase 1
Recruiting NCT04568291 - CTC in Lung Caner Patients With Bone Metastases N/A